Targeted delivery of drugs to the myometrium via polypeptides that bind to the oxytocin receptor

Patent metadata

Field	Value
Publication number	US-10952964-B2
Application number	US-201916435061-A
Country	US
Kind code	B2
Filing date	Jun 7, 2019
Priority date	May 23, 2013
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

Provided herein are methods and compositions for the targeted delivery to myometrial tissue of one or more agents capable of regulating contractility of myometrial tissue, wherein the one or more agents are contained or encapsulated within a polymeric delivery vehicle conjugated with one or more molecules that recognizes and/or is capable of binding, directly or indirectly, to the oxytocin receptor.

First claim

The invention claimed is:

1. A method for targeted delivery to myometrial tissue of one or more agents capable of inhibiting or reducing contractility of said myometrial tissue, comprising exposing myometrial tissue to an effective amount of the one or more agents, wherein the one or more agents are contained or encapsulated within a polymeric delivery vehicle conjugated with anti-oxytocin receptor antibodies or a peptide that binds to the oxytocin receptor,
wherein the polymeric delivery vehicles containing the agent(s) are administered to a pregnant female mammal, and
wherein the administration is to slow down labour or prevent premature labour.

2. A method according to claim 1 , wherein the polymeric delivery vehicle is a liposome.

3. A method according to claim 1 , wherein the polymeric delivery vehicle is coated with anti-oxytocin receptor antibodies or a peptide that binds to the oxytocin receptor.

4. A method according to claim 1 , wherein the anti-oxytocin receptor antibodies bind to an extracellular domain of the oxytocin receptor.

5. A method according to claim 1 , wherein the one or more agents are selected from calcium channel inhibitors, β 2 -adrenergic receptor agonists and phosphodiesterase inhibitors.

6. A method according to claim 5 , wherein the calcium channel inhibitor is nifedipine.

7. A method according to claim 5 , wherein the β 2 -adrenergic receptor agonist is salbutamol or ritodrine.

8. A method according to claim 5 , wherein the phosphodiesterase inhibitor is rolipram.

Assignees

• Univ Newcastle

Inventors

• Hua Susan
• Paul Jonathan
• Smith Roger

Classifications

• A61K31/18

  Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title

• A61K9/1271 Primary

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K47/6847

  the antibody targeting a hormone or a hormone-releasing or -inhibiting factor · CPC title

• A61P15/14

  for lactation disorders, e.g. galactorrhoea · CPC title